Clinical Trials
32 trialsMyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer
Ohio State University Comprehensive Cancer Center
EQUINOXE
Assistance Publique - Hôpitaux de Paris
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
Massachusetts General Hospital
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Big Ten Cancer Research Consortium
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Stanford University
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery
City of Hope Medical Center
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
OHSU Knight Cancer Institute
Parpvax
University of Pennsylvania
Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
PTCA199-6
Fudan University
PTCA199-7
Fudan University
PTCA199-11
Fudan University
Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study
Ohio State University Comprehensive Cancer Center
RadioFAP
French Society of Digestive Endoscopy
Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
SABER
Asan Medical Center
Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
OHSU Knight Cancer Institute
PDAC Peripheral and Portal Vein Sampling
The Christie NHS Foundation Trust
THERGAP-02
University Hospital, Toulouse
Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors
Instituto de investigación e innovación biomédica de Cádiz
Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
Kochi University
nITRo
Centro Ricerche Cliniche di Verona
Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer
Baylor Research Institute
Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.
Fudan University
Selective Transvenous Chemoembolization of Primary Pancreatic Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer
Asan Medical Center
Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery
Stanford University
GEMCAD1003
Grupo Espanol Multidisciplinario del Cancer Digestivo
REACT
Milton S. Hershey Medical Center
MOAnab1
Institut Paoli-Calmettes